17-Beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
申请人:Schering Corporation
公开号:US20030232837A1
公开(公告)日:2003-12-18
There are disclosed compounds of the formula (I):
1
prodrugs thereof, or pharmaceutically acceptable salts of the compounds or of said prodrugs which are useful as inhibitors of Type 3 17&bgr;-Hydroxysteroid Dehydrogenase. Also disclosed are pharmaceutical compositions containing said compounds and their use for the treatment or prevention of androgen dependent diseases.
PIPERIDINE- AND PIPERAZINEACETAMIDES AS 17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
申请人:Schering Corporation
公开号:EP1436281B1
公开(公告)日:2010-06-16
17 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
申请人:Schering Corporation
公开号:EP1572299B1
公开(公告)日:2008-09-24
17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
申请人:Guzi J. Timothy
公开号:US20080004248A1
公开(公告)日:2008-01-03
In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17β-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17β-hydroxysteroid dehydrogenase using such compounds or pharmaceutical compositions.